A new cancer drug may be able to inhibit both tumor growth and the spread of aggressive prostate cancer. This is shown in a ...
Blue Earth Therapeutics, a clinical-stage radiopharmaceutical company and University College London (UCL) today announced initiation of a Phase 1 clinical trial (NCT07414940) evaluating Actinium ...
FOX 13 Tampa Bay on MSN
Zephyrhills man with stage 4 metastatic prostate cancer finds strength, purpose on the pickleball court
For Gary Buchanan, pickleball is more than a game; it's a place where, for a few hours, he can set aside the reality of living with stage 4 cancer.
FDA concurrence supports US launch of a 2:1 randomized ~490-patient phase 3 comparing TLX591-Tx plus SOC versus SOC in ...
Irish Examiner on MSN
'Every effort must be made' to provide prostate cancer drug to public patients
Novartis manufacturers Pluvicto which benefits men with advanced prostate cancer, and oncologists have told the HSE that ...
Stockholm3 blood test detected 90% of aggressive prostate cancer cases compared to 74% for PSA tests in a study of over ...
MedPage Today on MSN
Recent developments in prostate cancer
Practice-changing perioperative therapy, chemo-free combo for CSPC, reducing cognitive eff ...
Hope for men with high-risk non-metastatic hormone resistant prostate cancerBy Dr Jacqueline Schmitt - Manager, Research ...
Morning Overview on MSN
Capivasertib won FDA approval for a hard-to-treat form of prostate cancer
Men diagnosed with metastatic prostate cancer that lacks the PTEN protein now have a targeted drug option for the first time.
The prostate is the single organ most frequently afflicted by cancer in men. Prostate cancer affects approximately 4 million ...
The metastatic prostate cancer market is undergoing a major transition from conventional ADT toward combination-based, biomarker-driven, and precision-targeted treatment approaches. While AR pathway ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results